Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

User Fee Conference Committee Targets Settling Differences In June

This article was originally published in The Tan Sheet

Executive Summary

A conference committee tackles differences between House and Senate FDA user fee and agency reform bills, with an agreement expected before the end of June.

Advertisement

Related Content

Bipartisan Support Pushes FDA User Fee Bill One Step From Passage
Bipartisan Support Pushes FDA User Fee Bill One Step From Passage
Foreign Regulatory Systems Can Be Strengthened By Receiving FDA Inspection Data, IOM Says
User Fee Package Offers FDA Reforms From A House Wary Of FDA Power
FDA Antibiotic Legislation Should Focus On Criteria, Not Bacteria, Woodcock Says
Biosimilars: FDA Trying Group-Think Negotiating Strategy For User Fee

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105798

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel